Grace Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price
Grace Therapeutics, Inc. (GRCE) had Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price of $1.08 per share as of 2023-03-31, per its 10-K filed 2023-06-23.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2023-06-23
- 2021-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price 1.76 CAD/shares.
- 2020-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price 0.00 CAD/shares.
- 2020-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price 0.76 CAD/shares; Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price as first filed 0.83 CAD/shares.
- 2019-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price 0.83 CAD/shares; Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price as first filed 1.05 CAD/shares.
CAD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2021-12-31 | 1.76 CAD/shares 10-Q · filed 2022-02-14 | |
| 2020-12-31 | 0.00 CAD/shares 10-Q · filed 2022-02-14 | |
| 2020-03-31 | 0.76 CAD/shares 10-K · filed 2021-06-22 | 0.83 CAD/shares 10-K · filed 2020-06-29 |
| 2019-03-31 | 0.83 CAD/shares 10-K · filed 2021-06-22 | 1.05 CAD/shares 10-K · filed 2020-06-29 |
USD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2023-03-31 | $1.08 10-K · filed 2023-06-23 | |
| 2022-06-30 | $0.99 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $1.51 10-K · filed 2023-06-23 | $1.91 10-K · filed 2022-06-21 |
| 2021-03-31 | $5.97 10-K · filed 2022-06-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |